The AI Churn Trap in Life Sciences and How to Break It

A costly pattern is emerging across artificial intelligence (AI) programs within life sciences that, if left unaddressed, could impact how quickly new therapies reach patients. Teams launch a pilot, pick a tool, and start building momentum. Then, before the last initiative is implemented, adopted, or delivering ROI, leadership pivots to the next “must do” AI priority. With 92% of clinical operations leaders increasing AI investment and 82% expecting 2-3x returns, it’s no surprise priorities and expectations keep shifting.

This AI churn, repeatedly restarting AI efforts instead of scaling what works, keeps organizations in constant motion with little measurable impact. To break out of it, leaders need to shift their mindset and treat AI as a capability that demands real follow-through, not just experimentation. Otherwise, organizations risk fragmentation, burned-out teams, and inconsistent governance: a missed opportunity to reduce trial timelines and costs.

Agentic AI is the latest phenomenon capturing attention, but far less forgiving than earlier waves of AI. Agents only deliver value when they can operate inside real trial workflows. That means systems have to be connected, integrations have to be in place, and the underlying data has to be reliable. Without this foundation, an agent cannot safely act or pass work from one step to the next. It either stalls, produces inconsistent outputs, or creates rework that erases any promised gains. In other words, if your data and processes are fragmented, agentic AI doesn't amplify productivity. It amplifies the friction already slowing studies down.

When this happens, the problem is rarely the model itself. In practice, organizational execution is what separates AI pilots from sustained results. Constant reprioritization prevents teams from finishing what they start and building on it. Vague definitions of success make it hard to prove value and even harder to scale. When change management cannot keep pace with the technology, adoption stalls. These factors leave AI stuck in pilots instead of improving trial execution and reducing delays.

AI churn is often driven by a familiar sequence. Leadership sets an aggressive implementation mandate, but the organization doesn’t get the time, resources, or execution support to match it. Teams respond by moving quickly into pilots, yet these efforts often begin without measurable outcomes, clear ownership, or an adoption plan, which makes it hard to align cross functional stakeholders around a single path to scale.

Each function then optimizes for its own needs, and the work stays fragmented instead of integrating into real workflows. In this environment, unclear goals also amplify human resistance, especially when AI is positioned primarily as an efficiency play rather than a clearly defined improvement to quality or speed.

Breaking the cycle requires a different playbook. The teams that consistently succeed treat AI as an operational capability and build it with the same discipline as any other critical part of trial execution. It starts with clarity on the outcome. Instead of deploying AI because it is available, they choose a specific problem to solve and define how success will be measured. From there, they plan deployments in a realistic sequence so each release strengthens the foundation for the next. They also establish ownership and governance early, so clinical, data, quality, and regulatory teams stay aligned as the work scales. Adoption is treated as part of the build, not an afterthought, by investing in training, communication, and feedback loops. Over time, they track usage and value, then use those signals to refine what is working and scale it sustainably.

Underlying all of this is a non-negotiable requirement: trust. In clinical trials, AI has to be clinically fluent and fit for specific purposes, not just an impressive demo. That means the system has to reflect clinical reality and be grounded in clinically relevant data. It also needs guardrails that improve output consistency and reduce hallucination risk by constraining responses to validated sources. In regulated workflows that handle sensitive patient data, this rigor is not optional. The organization must enforce it intentionally.

When an organization is caught in AI churn, the answer is to build an operating model that allows innovation to scale. Start with one or two workflows where value can be measured, define success before building, and assign clear accountability. Then see those deployments through to completion, with governance and validation in place from the beginning.

Design for adoption, not just deployment, and commit long enough to prove ROI and scale. From there, additional capabilities like AI agents can be layered in intentionally, backed by a functional, connected, and compliant foundation.

This shift is the prerequisite for unlocking the next generation of AI, including agentic systems, in a way that is safe, scalable, and worth the investment. Life science leaders need to make deliberate commitments, choose where AI will meaningfully change outcomes, and follow through all the way from implementation to validation to adoption.

When workflows are connected, data is trusted, and teams are aligned on what success looks like. AI stops being an experiment and starts improving the day-to-day realities of clinical development. This is how you get fewer delays, less rework, and faster, more predictable execution. Most importantly, it’s how innovation translates into better experiences for patients and sites, and into therapies that reach the people who need them sooner.

Lisa Moneymaker, Chief Operating and Strategy Officer at Medidata